Gabapentin
Product Images NDC 70518-3708

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-3708). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Mm2 (Gabapentin 500mg 10ml 70518 3708 01)

Mm2 (Gabapentin 500mg 10ml 70518 3708 01)
Gabapentin is a medication that comes as an oral solution with a concentration of 500mg/10 mL. It is packaged and distributed under the NDC code 70518-3708-01 and sourced from AcellaPharma in Alpharetta, GA 30022. The medication has to be refrigerated and kept out of reach of children. The lot number and expiration date are missing from the label. The package insert should be consulted before use. The medication was repackaged by RemedyRepack Inc. in Indiana, PA 15701.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
This is a prescription drug with Gabapentin, 250mg /5 mL, oral solution. It comes in a pack of 10 cups, each containing 10mL of the solution, and should be kept refrigerated. The manufacturer is AcellaPharma in Alpharetta, GA, and it was repackaged by RemedyRepack Inc. The package insert should be consulted for usage directions. The product should be kept out of reach of children, and stored at 2-8°C (364B°F), with excursions permitted to D-15°C (32-69°F) [See USP].*
FDA Label Image

Equation (Figure 01)

Equation (Figure 01)
This is a formula for calculating creatinine clearance (CLCr), which can be used to assess kidney function. The formula takes into account the patient's age and weight, as well as their serum creatinine level. The result should be adjusted for female patients by multiplying by 0.85.*
FDA Label Image

Chemical Structure (Figure 02)

Chemical Structure (Figure 02)
FDA Label Image

Figure 1 (Figure 03)

Figure 1 (Figure 03)
FDA Label Image

Figure 2 (Figure 04)

Figure 2 (Figure 04)
FDA Label Image

Figure 3 (Figure 05)

Figure 3 (Figure 05)
FDA Label Image

Figure 4 (Figure 06)

Figure 4 (Figure 06)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.